Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/9/2022 | $5.00 → $2.00 | Buy | BTIG |
| 12/20/2021 | $8.00 → $2.50 | Buy | Chardan Capital |
| 12/16/2021 | $2.00 | Buy | HC Wainwright & Co. |
| 9/15/2021 | $5.00 | Buy | BTIG |
4 - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Issuer)
4 - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Issuer)
3 - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Issuer)
Ms. McNeill is a former executive of Pfizer and an entrepreneur with expertise in marketing and public relations; she will sit on the Board of Directors and serve as the Chairperson of Sonnet's newly formed Business Advisory Committee (BAC)The BAC will advise the company on business collaborations, communications and interactions with the Federal GovernmentPRINCETON, NJ / ACCESSWIRE / September 26, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that Lori McNeill has been appointed to the Company's Board of Directors. Ms. McNeill's Board position will also round out the composition of the compan
PRINCETON, NJ / ACCESSWIRE / March 22, 2021 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today the appointment of Richard Kenney, M.D. as Chief Medical Officer and Manuel Dafonseca, as Head of Clinical Operations, effective March 22, 2021. "I am pleased to welcome Richard and Manuel to Sonnet at such an exciting time as we prepare to enter SON-1010, our proprietary fully human Interleukin 12 (IL-12) therapeutic candidate configured with our Fully Human Albumin Binding (FHAB) technology, into the clinic," said Pankaj Mohan, Ph.D., Founder and CEO. "Richard is a seasoned
4 - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Issuer)
4 - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Issuer)
8-K - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Filer)
424B4 - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Filer)
EFFECT - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Filer)
Drs. Pankaj Mohan, CEO of Sonnet, and John Cini, CSO of Sonnet, discuss the Company's recent issuance of a U.S. patent covering a variant of IL-18 incorporated into two novel immunotherapeutic drug candidates, SON-1400 and SON-1411 Watch the "What this Means" segment here PRINCETON, NJ, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the "Company" or "Sonnet") (NASDAQ:SONN), a clinical-stage company developing innovative targeted immunotherapeutic drugs, today announced that Pankaj Mohan, PhD, Chief Executive Officer of Sonnet, and John Cini, PhD, Chief Scientific Officer of Sonnet, participated in a Virtual Investor "What this Means" segment released by Sonnet.
PRINCETON, NJ, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the "Company" or "Sonnet") (NASDAQ:SONN), a clinical-stage company developing innovative targeted immunotherapeutic drugs, today announced the pricing of an underwritten public offering of 1,111,111 shares of common stock (or pre-funded warrants to purchase shares of common stock in lieu of shares of common stock) and common warrants to purchase up to an aggregate of 2,222,222 shares of common stock. Each share of common stock (or pre-funded warrant in lieu thereof) is being sold together with one common warrant at a combined offering price of $4.50, priced at-the-market under the rules of the Nasdaq St
Both novel bifunctional (SON-1411) and monofunctional (SON-1400) fusion proteins exhibit wild-type binding to the IL-18 receptor (IL-18Rc), coupled with undetectable binding to the inhibitory IL-18 binding protein (IL-18BP) IL-18 has significant importance for cancer immune-oncology and combination with IL-12 on Sonnet's FHAB platform which Sonnet believes could present an important oncology possibility The lock-and-load flexibility of the FHAB platform offers the bifunctional payload capability of adding another synergistic biologics target to IL-18 generating multiple novel cancer drugs PRINCETON, NJ, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc.
BTIG reiterated coverage of Sonnet BioTherapeutics with a rating of Buy and set a new price target of $2.00 from $5.00 previously
Chardan Capital reiterated coverage of Sonnet BioTherapeutics with a rating of Buy and set a new price target of $2.50 from $8.00 previously
HC Wainwright & Co. initiated coverage of Sonnet BioTherapeutics with a rating of Buy and set a new price target of $2.00
SC 13G/A - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Subject)
SC 13G/A - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Subject)
SC 13G/A - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Subject)
Data indicates that SON-080 was well-tolerated at both doses, with no evidence of a pro-inflammatory cytokine responsePain and quality of life survey results suggest the potential for rapid improvement of peripheral neuropathy symptoms and post-dosing durability with both doses, compared to placebo controlsSonnet intends to seek a partnership to support initiation of a Phase 2 clinical trial of SON-080 in Diabetic Peripheral Neuropathy (DPN), a mechanistically synergistic and larger, high-value indication with unmet medical needManagement highlights data findings in a Virtual Investor "What This Means" segment
Gainers DermTech (NASDAQ:DMTK) stock rose 56.6% to $0.18 during Friday's pre-market session. The market value of their outstanding shares is at $6.4 million. Sarepta Therapeutics (NASDAQ:SRPT) shares rose 39.26% to $171.99. The market value of their outstanding shares is at $16.2 billion. Kintara Therapeutics (NASDAQ:KTRA) shares increased by 17.78% to $0.32. The market value of their outstanding shares is at $17.9 million. Solid Biosciences (NASDAQ:SLDB) stock moved upwards by 17.3% to $7.39. The market value of their outstanding shares is at $283.6 million. ASLAN Pharma (NASDAQ:ASLN) stock rose 14.06% to $0.36. The market value of their outstanding shares is at $8.2 million. Alaunos
U.S. stocks traded mixed toward the end of trading, with the Dow Jones index gaining more than 300 points on Thursday. The Dow traded up 0.87% to 39,171.26 while the NASDAQ fell 0.65% to 17,745.523. The S&P 500 also fell, dropping, 0.14% to 5,479.13. Check This Out: Workday To Rally Over 52%? Here Are 10 Top Analyst Forecasts For Thursday Leading and Lagging SectorsEnergy shares jumped by 2% on Thursday. In trading on Thursday, information technology shares fell by 1.1%. Top Headline The EIA said stocks of crude oil in the U.S. declined by 2.547 million barrels in the week ending June 14, compared to market estimates of a 2.800 million barrels decline. Equities Trading